CliffordAHudisMD

PubMed

• Flashback Foreword: Preoperative Therapy for Operable Breast Cancer and Clinical Features of Triple-Negative Breast Cancer.
  Clifford A Hudis> ;Journal of Clinical Oncology. 2023 Apr 1
• 34 citations
  Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
  Tolaney, S., Tarantino, P., Graham, N., Tayob, N., Parè, L., Villacampa, G., Dang, C., Yardley, D., Moy, B., Marcom, P., Albain, K., Rugo, H., Ellis, M., Shapira, I., ...> ;The Lancet. Oncology. 2023 Mar 1
• 39 citations
  CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab i...
  Jonathan H Shepherd, Karla Ballman, Mei-Yin C Polley, Jordan D Campbell, Cheng Fan, Sara Selitsky, Aranzazu Fernandez-Martinez, Joel S Parker, Katherine A Hoadley, Zhi...> ;Journal of Clinical Oncology. 2022 Apr 20
• 6 citations
  The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention.
  Linda M Delahanty, Thomas A Wadden, Pamela J Goodwin, Catherine M Alfano, Cynthia A Thomson, Melinda L Irwin, Marian L Neuhouser, Tracy E Crane, Elizabeth Frank, Patri...> ;Obesity. 2022 Jan 1
• 1 citations
  Retraction: Increased Levels of COX-2 and Prostaglandin E2 Contribute to Elevated Aromatase Expression in Inflamed Breast Tissue of Obese Women.
  Kotha Subbaramaiah, Patrick G Morris, Xi Kathy Zhou, Monica Morrow, Baoheng Du, Dilip Giri, Levy Kopelovich, Clifford A Hudis, Andrew J Dannenberg> ;Cancer Discovery. 2021 May 1
• 6 citations
  Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance).
  Jennifer A. Ligibel, Luke Huebner, Hope S. Rugo, Harold J. Burstein, Debra L Toppmeyer, Carey K. Anders, Cynthia X. Ma, William T. Barry, Vera J. Suman, Lisa A. Carey,...> ;JNCI Cancer Spectrum. 2021 Apr 12
• 20 citations
  Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy
  Mark Jesus M. Magbanua, Laura H. Hendrix, Terry Hyslop, William T. Barry, Eric P. Winer, Clifford A. Hudis, Deborah Toppmeyer, Lisa A. Carey, Ann H. Partridge, Jean-Yv...> ;Journal of the National Cancer Institute. 2021 Apr 6
• 62 citations
  Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positi...
  Aranzazu Fernandez-Martinez, Ian E. Krop, David W. Hillman, Mei Yin C. Polley, Joel S. Parker, Lucas J. Huebner, Katherine A. Hoadley, Jonathan Shepherd, Sara M. Tolan...> ;Journal of Clinical Oncology. 2020 Oct 23
• 13 citations
  First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer
  Mark Dunphy, Christina Pressl, Nagavarakishore Pillarsetty, Milan Grkovski, Shanu Modi, Komal Jhaveri, Larry Norton, Bradley J. Beattie, Pat Zanzonico, Danuta Zatorska...> ;Clinical Cancer Research. 2020 May 4
• 17 citations
  Bridging the Gap Among Clinical Practice Guidelines for Pain Management in Cancer and Sickle Cell Disease
  Alyssa A. Schatz, Thomas K. Oliver, Robert A. Swarm, Judith A. Paice, Deepika S. Darbari, Deborah Dowell, Salimah H. Meghani, Katy Winckworth-Prejsnar, Eduardo Bruera,...> ;Journal of the National Comprehensive Cancer Network. 2020 Apr 1
• 1 citations
  Bridging the Gap Among Clinical Practice Guidelines for Pain Management in Cancer and Sickle Cell Disease
  Alyssa A. Schatz, Thomas K. Oliver, Robert A. Swarm, Judith A. Paice, Deepika S. Darbari, Deborah Dowell, Salimah H. Meghani, Katy Winckworth-Prejsnar, Eduardo Bruera,...> ;JCO Oncology Practice. 2020 Apr 7
• Reply to M. Hutton-Potts and A.M. Joshua.
  Clifford A. Hudis, Richard L. Schilsky> ;JCO Oncology Practice. 2020 Apr 2
• 4 citations
  Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)
  Manish R. Sharma, Shailly Mehrotra, Elizabeth Gray, Kehua Wu, William T. Barry, Clifford A. Hudis, Eric P. Winer, Alan P. Lyss, Deborah Toppmeyer, Alvaro Moreno-Aspiti...> ;Journal of Clinical Pharmacology. 2020 Apr 1
• 89 citations
  Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors.
  Pedram Razavi, Maura N. Dickler, Payal D. Shah, Weiyi Toy, David N Brown, Helen Won, Bob T. Li, Ronglai Shen, Neil Vasan, Shanu Modi, Komal Jhaveri, Betty Ann Caravell...> ;Nature Cancer. 2020 Mar 23
• 19 citations
  Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor–Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance)
  E. Shelley Hwang, Terry Hyslop, Laura H. Hendrix, Stephanie Duong, Isabelle Bedrosian, Elissa R. Price, Abigail S. Caudle, Tina J. Hieken, J. M. Guenther, Clifford A. ...> ;Journal of Clinical Oncology. 2020 Mar 3
• 1 citations
  Retraction: Withdrawal: EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells: Evidence of a BRCA1 and p300 exchange (The Jou...
  Kotha Subbaramaiah, Clifford A. Hudis, Sung Hee Chang, Timothy Hla, Andrew J. Dannenberg> ;The Journal of Biological Chemistry. 2020 Jan 3
• 2 citations
  Discrepancies in Financial Self-Disclosures and Open Payments Reporting Among Authors of Clinical Oncology Research Studies.
  Elizabeth Garrett-Mayer, Melinda Kaltenbaugh, Rebecca Spence, Suanna S. Bruinooge, Clifford A. Hudis, Dina L. Michels, Richard L. Schilsky> ;Journal of Clinical Oncology. 2020 Feb 10
• 4 citations
  Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Po...
  Neil M. Iyengar, Lillian M. Smyth, Diana Lake, Ayca Gucalp, Jasmeet C. Singh, Tiffany A. Traina, Patricia DeFusco, Monica Fornier, Shari Goldfarb, Komal Jhaveri, Shanu...> ;JAMA Network Open. 2019 Nov 1
• 16 citations
  Hydroxyapatite mineral enhances malignant potential in a tissue-engineered model of ductal carcinoma in situ (DCIS)
  Frank He, Nora L. Springer, Matthew Whitman, Siddharth P. Pathi, Yeonkyung Lee, Sunish Mohanan, Stephen Marcott, Aaron E. Chiou, B. Blank, Neil M. Iyengar, Patrick G. ...> ;Biomaterials. 2019 Sep 11
• 14 citations
  Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the ...
  Miguel Martin, S. Loibl, Terry Hyslop, J. de la Haba-Rodríguez, Bahriye Aktas, Constance Cirrincione, Keyur Mehta, William T. Barry, Serafin Morales, Lisa A. Carey, Jo...> ;European Journal of Cancer. 2019 Aug 1
• 1 citations
  Real transparency in medicine: Time to act
  Clifford A. Hudis, Robert W. Carlson> ;Cancer. 2019 Nov 15
• 41 citations
  Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.
  Hyman B. Muss, Mei Yin C. Polley, Donald A. Berry, Heshan Liu, C. Cirrincione, Maria Theodoulou, Ann M. Mauer, Alice B. Kornblith, Ann H. Partridge, Lynn G. Dressler, ...> ;Journal of Clinical Oncology. 2019 Jul 24
• 16 citations
  Copper-64 trastuzumab PET imaging: a reproducibility study.
  Jorge A. Carrasquillo, Patrick G. Morris, John L. Humm, Peter Smith-Jones, Volkan Beylergil, Tim Akhurst, Joseph A. O'Donoghue, Shutian Ruan, Shanu Modi, Clifford A. H...> ;The Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2019 Jun 1
• 23 citations
  Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)
  Jennifer R. Bellon, Hao Guo, William T. Barry, Chau T. Dang, Denise A. Yardley, Beverly Moy, P. Kelly Marcom, Kathy S. Albain, Hope S. Rugo, Matthew J. Ellis, Antonio ...> ;Breast Cancer Research and Treatment. 2019 Apr 19
• 164 citations
  Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
  Sara M. Tolaney, Hao Guo, Sonia Pernas, William T. Barry, Deborah A. Dillon, Lauren L. Ritterhouse, Bryan P. Schneider, Fei Shen, Kit Fuhrman, Michele Baltay, Chau T. ...> ;Journal of Clinical Oncology. 2019 Apr 2
• Join now to see all

Journal Articles

• Science and Society: Fifty Years Later-The 2014 Presidential Address  
  Hudis C, J Clin Oncol, 1/10/2015
• A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer  
  Jhaveri K, Chandarlapaty S, Lake D, Gilewski T, Robson M, Goldfarb S, Drulinsky P, Sugarman S, Leiblich CW, Fasano J, Moynahan ME, D'Andrea G, Lim K, Reddington L, Haq..., Clin Breast Cancer, 1/1/2014
• Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901  
  Faul LA, Luta G, Sheppard V, Isaacs C, Cohen HJ, Muss HB, Yung R, Clapp JD, Winer E, Hudis C, Tallarico M, Wang J, Barry WT, Mandelblatt JS, J Cancer Surviv, 1/1/2014
• Building a rapid learning health care system for oncology: the regulatory framework of Cancer LinQ  
  Schilsky RL, Michels DL, Kearbey AH, Yu PP, Hudis CA, J Clin Oncol, 1/1/2014
• Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update  
  Burstein HJ, Temin S, Anderson H, Bucholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ, J Clin Oncol, 1/1/2014
• Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic ...  
  Sikov Wm, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA,..., J Clin Oncol, 1/1/2014
• American Society of Clinical Oncology Position Statement on Obesity and Cancer  
  Ligibel JA, Alfano CM, Couneya KS, Demark-Wahnefried W, Burger RA, Chlebowski RT, Fabian CJ, Gucalp A, Hershman DL , Hudson MM, Jones LW, Kakarala M, Ness KK, Merrill ..., J Clin Oncol, 1/1/2014
• Web based pathology assessment in RTOG 98-04  
  Woodward WA, Sneige N, Winter K, Kuerer HM, Hudis C, Rakovitch E, Smith BL, Pierce LJ, Germano I, Pu AT, Walker EM, Grisell DL, White JR, McCormick B for the Radiatio..., J Clin Pathology, 1/1/2014
• Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB...  
  Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EP, J Clinc Oncology, 1/1/2014
• Genome sequencing of multiple primary tumors reveals a novel PALB2 variant  
  Schrader KA, Stratton KL, Murali R, Laitman Y, Cavallone L, Offit L, Wen YH, Thomas T, Shah S, Rau-Murthy R, Manschreck C, Sal0Mullen E, Otegbeye E, Corines M, Zhang L..., J Clinc Oncology, 1/1/2014
• Breast cancer version 32014  
  Gradishar WJ, Anderson Bo, Blair SL, Burstien JH, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK,..., J Natl Compr Netw, 1/1/2014
• Comorbidity, chemotherapy toxicity and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361104 (...  
  Klepin HD, Pitcher BN, Balmman KIV, Kornblith AB, Hurria A, Winer EP, Hudis C, Cohen HJ, Muss HB, Kimmick GG, J Oncol Pract, 1/1/2014
• Sequester cuts may delay drug approvals - and more  
  Hudis CA, Sci Trans Med, 1/1/2014
• A phase 3 tRial comparing capecitabine E in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatic HER2-Negative breast CancEr (the RESI...  
  Baselga J, Costa F, Gomez H, Hudis CA, Rapoport B, Roche H, Schwartzberg LS, Petrenciuc O, Shan M, Gradishar WJ, Trials, 1/1/2013
• Risk of metaschronous breast cancer after BRCA mutation-associated ovarian cancer  
  Domchek SM, Jhaveri K, Patil S, Stopfer JE, Hudis C, Powers J, Stadler Z, Goldstein L, Kauff N, Khasraw M, Offit K, Nathanson KL, Robson M, Cancer, 1/1/2013
• Risk of metachronous breast cancer after BRCA mutation0 associated ovarian cancer  
  Domeck SM, Jhaveri K, Patil S, Stopfer JE, Hudis C, Powers J, Stadler Z, Goldstein L, Kauff N, Khasraw M, Offit K, Nathanson KL, Robson M, Cancer, 1/1/2013
• Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer  
  De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Maric-Bernstam F, Meszoely IM, Nanda R, Hwang ES, Cancer, 1/1/2013
• Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer  
  Ulaner GA, Eaton A, Morris PG, Lilienstein J, Jhaveri K, Patil S, Fazio M, Larson S, Hudis CA, Jochelson MS, Cancer Medicine, 1/1/2013
• Caloric restriction reverses obesity induced mammary gland inflammation in mice  
  Bhardwaj P, Baoheng Du, Xi KZ, Sue E, Harbus MD, Falcone DJ, Giri D, Hudis CA, Kopelovich, L, Cancer Prev Res, 1/1/2013
• Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer  
  Morris PG, Zhou XK, Milne GL, Goldstein D, Hawks LC, Dang CT, Modi S, Fornier MF, Hudis CA, Dannenberg AJ, Cancer Prev Res, 1/1/2013
• Dietary polyphenols suppress elevated levels of proinflammatory mediators and aromatase in the mammary gland of obese mice  
  Subbaramaiah K, Sue E, Bhardwaj P, Du B, Hudis CA, Giri D, Kopelovich L, Zhou XK, Dannenberg A, Cancer Prev Res, 1/1/2013
• Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging and lung metastases in patients with breast cancer  
  Morris PG, Zhou XK, Milne GL, Goldstein D, Hawks LC, Dang CT, Modi S, Fornier, MN, Hudis CA, Dannenberg AJ, Cancer Prev Res, 1/1/2013
• Randomized Phase II Trial of Weekly Versus Every 2 Weeks Versus Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Met...  
  Seidman AD, Conlin AK, Bach A, Moynahan ME, Lake D, Forero A, Wright GS, Hackney MH, Clawson A, Norton L, Hudis, C, Clin Breast Cancer, 1/1/2013
• Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer  
  Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ, Clin Breast Cancer, 1/1/2013
• Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab  
  Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani V, Stepanski EJ, Rugo H, Wang W, Bell-McGuinn K, Kirshner J, Eisenberg PD, Emanuel..., Clin Cancer Res, 1/1/2013
• Join now to see all

Books/Book Chapters

• Diseases of the Breast 
  Chapter: Adjuvant systemic chemotherapy in early breast cancer. 
  Page 635 - 648Hudis CA, Dang CEditors: Harris JR, Lippman ME, Morrow, M Osborne CK.Lippincott, Williams & Wilkins, Philadelphia, PAEdition 5th,2014
• Diseases of the Breast 
  Chapter: Implications of breast cancer. 
  Page 700 - 708Gucalp A, Morris PG, Hudis CA, Dannenberg AJEditors: Harris JR, Lippman ME, Morrow, M Osborne CK.Lippincott, Williams & Wilkins, Philadelphia, PAEdition 5th,2014
• Emerging Cancer Therapeutics 
  Chapter: Adjuvant chemotherapy for breast cancer: updates and new perspectives. 
  Page 495 - 507Murphy C, Hudis CA, McArthur HLEditors: Tan AR.Demos Medical Publishing, New York, NY2011
• Future of Medicine 
  Chapter: Advances in Management of Triple Negative. 
  Hudis C, Traina TAEditors: Tiffany Traina.Future Medicine Ltd, London, United Kingdom2011
• New treatment paradigms in metastatic breast cancer 
  Dang C and Hudis C (Eds)Editors: Dang C and Hudis C.CMPMedica, London, England2008
• Breast Cancer 
  Winchester DJ, Winchester DP, Hudis C, Norton L (Eds)Editors: Winchester DJ, Winchester DP, Hudis C, Norton L.BC Decker, Hamilton, Ontario, CanadaEdition 2nd,2006
• Principles and Practice of Gynecologic 
  Chapter: Breast Cancer. 
  Page 1077 - 1170McCormick B, Hudis C, Gemignani M, Dershaw DD, Tan LK, Perez CA, Taylor MEEditors: Hoskins WJ, Perez CA, Young RC, Barakat R, Markman M, Randall M.Lippincott Williams & Wilkins, Philadelphia, PAEdition 4th,2005
• Progress in Oncology 
  Chapter: The concept of dose density and its application to the adjuvant chemotherapy of node-positive primary breast cancer. 
  Page 290 - 318Norton L, Hudis CEditors: Devita VT Jr, Hellman S, Rosenberg SA.Jones and Bartlett Publishers, Sudbury, MA2005
• Principles and Practice of Gynecologic Oncology 
  Chapter: Breast Cancer. 
  Page 1077 - 1170McCormick B, Hudis C, Gemignani M, Dershaw DD, Tan LK, Perez CA, Taylor MEEditors: Hoskins WJ, Perez CA, Young RC, Barakat R, Markman M, Randall M.Lippincott Williams & Wilkins, Philadelphia, PAEdition 4th,2005
• Breast Cancer 
  Chapter: Systemic Treatment for Stage I and Stage II Breast Cancer. 
  Page 537 - 556Hudis C and Norton LEditors: Roses DF.Elsevier, Philadelphia, PA2005
• Diseases of the Breast 
  Chapter: Rare Cancers in the Breast. 
  Page 1015 - 1033Hudis C, Tan LKEditors: Harris JR, Lippman ME, Morrow M, Osborne CK.Lippincott, Williams & Wilkins, Philadelphia, PAEdition 3rd,2004
• Progress in Anti-Cancer Chemotherapy. Volume IV 
  Chapter: How Should We Integrate New Drugs in the Treatment of Metastatic Breast Cancer? 
  Page 225 - 231Hudis CEditors: Khayat D, Hortobagyi GN.Blackwell-Science, Malden, MA2000
• ASCO Educational Book 
  Chapter: Chemotherapy for Early-stage Breast Cancer. 
  Page 266 - 273Hudis CEditors: Perry MC.American Society of Clinical Oncology, Alexandria, VA2000
• Principle and Practice of Gynecologic Oncology 
  Chapter: Breast Cancer. 
  Page 1139 - 1239McCormick B, Hudis C, Heerdt A, Borgen PI, Dershaw DD, Tan LK, Perez CA, Taylor MEEditors: Hoskins WJ, Perez CA, Young RC.Lippincott Williams & Wilkins, Philadelphia, PAEdition 3rd,2000
• Textbook of Breast Cancer: A Clinical Guide to Therapy 
  Chapter: Conventional Adjuvant Chemotherapy. 
  Page 139 - 149Hudis CEditors: Bonadonna G, Hortobagyi GN, Gianni AM.Martin Dunitz Ltd, London, United KingdomEdition 2nd,2000
• Breast Cancer 
  Chapter: Systemic Treatment of Stage I and Stage II Breast Cancer. 
  Page 417 - 444Hudis C, Norton LEditors: Roses DF.Churchill Livingstone, Philadelphia, PA1999
• Should this Woman Receive Postmastectomy Adjuvant Therapy? 
  Hudis C1994
• Mediguide to Oncology 
  Chapter: Metastatic Breast Cancer 
  Hudis C, Norton LEditors: Weirnik PH.1993
• Adjuvant Therapy of Cancer VII 
  Chapter: Dose-Intensive Sequential Crossover Adjuvant Chemotherapy for Women with High Risk Node-Positive Breast Cancer. 
  Page 214 - 219Hudis C, Lebwohl D, Crown J, Gilewski T, Surbone A, Hakes T, Currie V, Seidman A, Reichman B, Harrison M, Bellittieri R, Hamilton N, Norton LEditors: Salmon SE.JB Lippincott Company, Philadelphia, PA1993
• Current topics in surgical oncology 
  Chapter: Current status of Adjuvant Chemotherapy in the Treatment of Colorectal Cancer. 
  Page 485 - 502Hudis C, Kelsen DEditors: Fegiz, G, Ramacciato, G, Vitelli, C, De Angelis, R.Masson S.P.A., Milan, Italy1991
• Join now to see all

Lectures

• Continuing Medical Education (CME) Comprehensive Oncology Review 
  Continuing Medical Education Institute, Inc, Seattle, Washington - 9/22/2012

Other

• Dose-dense chemotherapy: ready for prime time. 
  Dang CT and Hudis CA, Breast Cancer Online
  http://www.bco.org/my_bco.asp
  1/1/2005
• Letrozole after tamoxifen improves disease-free survival from women with breast cancer (expert comments). 
  Hudis C
  www.breastcancercare.org